FTSE 250 movers: Broker notes spur on big movers
15th Dec 2015 15:24
(ShareCast News) - The FTSE 250 looks to finish the day in the green, with the second-tier market up 228.85 point (1.36%) to 17,001.42 mid-afternoon Tuesday. Circassia Pharmaceuticals rose to the top of the ranks after RBC Capital Markets initiated coverage at 'top pick' for the company. "With intr
Read moreCircassia appoints new non-exec director
9th Dec 2015 08:12
(ShareCast News) - Marvin Samson has been appointed as non-executive director of Circassia Pharmaceuticals, the FTSE 250 group said on Tuesday. Samson, the founder and current chief executive of Samson Medical Technologies, currently holds the role of non-executive director at Antares Pharma, Flynn
Read moreCircassia confident of meeting annual targets as sales rise in first nine months of 2015
27th Oct 2015 08:13
(ShareCast News) - Circassia Pharmaceuticals said it was confident of meeting its full-year expectations after sales of its asthma treatment rose in the latest quarter and in the first nine months of the year. In a trading update released on Tuesday, the FTSE 250 group said in the first nine months
Read moreCircassia makes unconditional offer for Aerocine
15th Jun 2015 14:12
Circassia Pharmaceuticals has officially declared an unconditional offer for Aerocrine and extended its acceptance period until 26 June. During the acceptance period, roughly 6.5m shares have been tendered, representing 93% of shared and voting rights in Aerocrine. Circassia first made a public cas
Read moreCircassia Pharmaceuticals to acquire Aerocrine and Prosonix
15th May 2015 10:36
Biopharmaceutical group Circassia Pharmaceuticals has announced it will make a £139m cash bid for Swedish group Aerocrine. The London-listed company said the offer for Aerocrine, a developer of medical diagnostic products for use in the diagnosis and management of patients with asthma, was part of i
Read moreWednesday broker round-up UPDATE
18th Jun 2014 09:03
Ashtead Group: Barclays ups target price from 930p to 946p retaining its overweight rating. Berkeley Group: Numis upgrades from hold to buy with a target price of 2491p. Brown (N) Group: Oriel places its buy recommendation under review. BT Group: Jefferies ups target price from 440p to 470p and k
Read moreCircassia Pharmaceuticals hails 'biggest ever' UK biotech IPO
13th Mar 2014 10:04
Allergy treatment developer Circassia Pharmaceuticals has confirmed it is raising 200m pounds in its initial public offering, as conditional trading between brokers began on Thursday morning. The biotech firm, which was spun out of university technology transfer group Imperial Innovations, priced
Read more